New hope for blood cancer patients: STP938 trial targets tough cases
NCT ID NCT06786234
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests STP938, a daily pill, in 50 adults with high-risk essential thrombocythaemia who cannot use standard therapy. The goal is to see if it safely lowers high platelet counts and reduces complications like blood clots. Participants take the drug for up to 12 months with regular clinic visits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
STP938
What this could lead to
If it works, this could offer a new treatment option for people with essential thrombocythaemia who cannot take or do not respond to current therapy.
What could go wrong
This is an early Phase 2 trial with only 50 participants, so results may not apply to everyone. The drug may cause side effects or fail to control platelet counts long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESSENTIAL THROMBOCYTHAEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CHU Brest
RECRUITINGBrest, France
-
CHU Nantes
RECRUITINGNantes, France
-
CHU Nice
RECRUITINGNice, France
-
CHU Nîmes
RECRUITINGNîmes, France
-
Cancer and Haematology Centre, Churchill Hospital
RECRUITINGOxford, OX3 7LE, United Kingdom
-
Gustave Roussy
RECRUITINGVillejuif, France
-
Hôpital Saint-Louis
RECRUITINGParis, France
-
Hôpital de la Milétrie, CHU
NOT_YET_RECRUITINGPoitiers, New Aquitaine, 86021, France
-
Imperial College London / Hammersmith Hospital
RECRUITINGLondon, United Kingdom
-
Institut Paoli-Calmettes
RECRUITINGMarseille, France
-
Royal Hallamshire Hospital
RECRUITINGSheffield, South Yorkshire, S10 2JF, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sarah Cannon Research Institute
RECRUITINGLondon, United Kingdom
-
University Hospital of Wales
RECRUITINGCardiff, United Kingdom
-
University of Southampton Hospital
RECRUITINGSouthampton, United Kingdom